We aspire to enable biopharma companies to exceed their goals in developing and delivering life-transforming nucleic-acid therapies, through production and GMP manufacturing of biopharmaceutical drug substances.

Global academic and industry collaborations are supporting sapientis in establishing a premier ecosystem to enable scientific progress and shared learning to speed up the availability of biotechnological solutions. Application include infectious diseases, immunotherapies against cancer, and precision medicine in rare diseases. Pilot projects will deliver products for clinical trial activities.

sapientis is planning to start operating the state-of-the-art cGMP biotechnological pilot plant including development laboratories as from Q4 2023 to provide comprehensive GMP development and the complete spectrum of services from discovery to drug substance and drug product development and manufacturing for New Biological Entities (NBEs) worldwide.